Page 13 - Interim Analysis News Today

/PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces its results for the fourth quarter and full year 2020. A live webcast presentation by Nordic...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial ... BIOPHYTIS SAFebruary 17, 2021 GMT Clinical centers in France and Belgium will begin recruitment for Part 2 of the COVA Study following authorization from Regulatory Authorities These approvals follow the previous authorizations obtained from Brazil and the United States in most clinical centers Interim Anal...

Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) Following Regulatory Authorities Approvals in France and Belgium - read this article along with other careers information, tips and advice on BioSpace

Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) Following Regulatory Authorities Approvals in France and Belgium February 17, 2021 02:00 ET | Source: BIOPHYTIS SA BIOPHYTIS SA Romainville, FRANCE Clinical centers in France and Belgium will begin recruitment for Part 2 of the COVA Study following authorization from Regulatory Authorities These approvals follow the previous authorizations o...

Biophytis Announces the Start of Patient Recruitment in Brazil and the USA for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) Patient recruitment in Part 2 of the COVA Study will begin in most clinical centers in Brazil and the United States Interim Analysis of Part 1 is expected in Q1 2021 Results from the full study (Part 1 and Part 2) are expected in Q2 2021 /EIN News/ -- PARIS and CAMBRIDGE, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a cli...

Published: Feb 03, 2021 Patient recruitment in Part 2 of the COVA Study will begin in most clinical centers in Brazil and the United States Interim Analysis of Part 1 is expected in Q1 2021 Results from the full study (Part 1 and Part 2) are expected in Q2 2021 PARIS and CAMBRIDGE, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Cassava Sciences’ Simufilam Improves Cognition and Behavior in Alzheimer’s Disease in Interim ... Cassava Sciences, Inc.February 2, 2021 GMT - Patients’ Cognition Improved 1.6 Points on ADAS-Cog11 - - Patients’ Behavior Improved 1.3 Points on NPI - - Improvements Maintained at 6 Months - - Results Support Advancing Simufilam into Phase 3 Clinical Program - AUSTIN, Texas, Feb. 02, 2021 (GLOBE ...

Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released An investigational COVID-19 vaccine developed by Janssen Pharmaceuticals appears to be safe and effective at preventing moderate and severe COVID-19 in adults, according to an interim analysis of Phase 3 clinical data conducted Jan. 21. The vaccine, called Ad.26.COV2.S or JNJ-78436725, requires only a single injection and can be stored in a refrigerator for months. The interim analysis assessed 468 case...

Preliminary analysis (n=176) demonstrates favorable safety and tolerability; data provide a strong signal of clinical benefit for subjects reporting one or more comorbidities Topline data from full study population of 350 patients and results of second study of KB109 are expected in the first quarter of 2021 LEXINGTON, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced positive interim results from the K031 non-IND controlled clinical study evalua...